Kaposi lesions - Causes, Treatment & When to See a Doctor

What is Kaposi lesions?

Kaposi lesions are vascular skin growths that appear as reddish, purple, or brown patches, plaques, or nodules on the skin, mucous membranes, or internal organs. They are the cutaneous manifestation of Kaposi sarcoma (KS), a neoplasm that arises from endothelial cells lining blood vessels. While KS is most famously associated with advanced HIV infection, it can also develop in other settings where the immune system is compromised or when the causative virus, human herpesvirus‑8 (HHV‑8), is present. The lesions can be painless or tender and may bleed or ulcerate if traumatized.

The disease was first described by Moritz Kaposi in 1872 as a “pigmented sarcoma” in elderly Mediterranean men. Today, we recognize several epidemiologic forms that differ in risk factors, clinical course, and prognosis. Understanding the underlying cause is essential for proper management and for preventing complications.

Common Causes

Kaposi lesions develop in the context of one of several recognized clinical variants:

• Classic (Mediterranean) Kaposi sarcoma – Occurs in older men of Eastern European, Mediterranean, or Middle‑Eastern descent; usually indolent.
• AIDS‑associated (epidemic) Kaposi sarcoma – Linked to HIV infection; lesions may be extensive and aggressive.
• Endemic (African) Kaposi sarcoma – Seen in sub‑Saharan Africa; can affect children and adults, sometimes without HIV.
• Iatrogenic (transplant‑related) Kaposi sarcoma – Develops after solid‑organ or bone‑marrow transplantation because of immunosuppressive therapy.
• HHV‑8 infection alone – The virus is necessary but not sufficient; some individuals carry HHV‑8 without ever developing lesions.
• Immunosuppressive medications – Long‑term corticosteroids, azathioprine, cyclosporine, or biologics can lower immune surveillance and allow KS to arise.
• Chronic inflammatory conditions – Rarely reported in patients with autoimmune diseases such as systemic lupus erythematosus.
• Genetic susceptibility – Certain HLA types and polymorphisms may increase risk, especially in endemic regions.
• Co‑infection with other oncogenic viruses – Epstein‑Barr virus (EBV) or hepatitis C virus can modify immune function and contribute to KS development.
• Age‑related immune senescence – The decline of immune function with age may partially explain classic KS in the elderly.

Associated Symptoms

Kaposi lesions may be isolated to the skin, but they often coexist with systemic findings:

• Lesions on oral mucosa, especially the palate or gingiva, causing pain or difficulty eating.
• Lymphadenopathy (enlarged lymph nodes), particularly in the neck or groin.
• Respiratory symptoms—cough, shortness of breath, or hemoptysis—when lesions involve the lungs.
• Gastrointestinal bleeding, abdominal pain, or weight loss if the GI tract is affected.
• Edema of the lower extremities from lymphatic obstruction.
• Fever, night sweats, and unexplained fatigue, especially in HIV‑positive patients.
• Occasional neurological signs (headache, seizures) when central nervous system lesions are present.

When to See a Doctor

Prompt medical evaluation is advisable if you notice any of the following:

• New or rapidly growing reddish‑purple spots on the skin or inside the mouth.
• Lesions that bleed, ulcerate, or become painful without an obvious cause.
• Persistent cough, shortness of breath, or coughing up blood.
• Unexplained weight loss, abdominal pain, or gastrointestinal bleeding.
• Swollen lymph nodes that do not resolve within a few weeks.
• Any skin changes in the setting of HIV infection, organ transplantation, or long‑term immunosuppressive therapy.

Early detection improves treatment outcomes, especially for epidemic and iatrogenic forms where disease can progress quickly.

Diagnosis

Diagnosing Kaposi lesions involves a combination of clinical assessment and laboratory testing:

1. Clinical Examination

• Full‑body skin survey to document lesion number, size, distribution, and morphology.
• Oral cavity, genital, and, when indicated, endoscopic examination of the gastrointestinal tract.

2. Skin or Tissue Biopsy

The gold standard is a punch or excisional biopsy. Histopathology typically shows spindle‑ shaped endothelial cells, slit‑like vascular spaces, and hemosiderin‑laden macrophages. Immunohistochemical staining for HHV‑8 latent nuclear antigen‑1 (LANA‑1) confirms the viral etiology.

3. Laboratory Tests

• HIV screening and viral load testing (if status unknown).
• CD4+ T‑cell count for HIV‑positive patients to gauge immune competence.
• Serology for HHV‑8 (limited availability; mainly used in research).
• Complete blood count, liver function tests, and renal panel to assess baseline organ function before systemic therapy.

4. Imaging Studies

• Chest X‑ray or CT scan for pulmonary involvement.
• Abdominal CT or PET/CT to evaluate visceral disease (liver, spleen, gastrointestinal tract).
• Brain MRI if neurologic symptoms suggest CNS lesions.

Treatment Options

Treatment is individualized based on disease extent, immune status, and patient preference. Options range from watchful waiting for indolent lesions to aggressive systemic therapy for disseminated disease.

Local Therapies (for limited skin disease)

• Cryotherapy – Liquid nitrogen freezes small lesions, offering quick removal with minimal scarring.
• Electrocautery or laser ablation – Useful for raised plaques or nodules.
• Topical imiquimod – An immune‑modulating cream approved for superficial KS in some countries.
• Radiation therapy – Low‑dose external beam radiation can shrink lesions that are painful or cosmetically concerning.

Systemic Therapies (for extensive or visceral disease)

• Antiretroviral therapy (ART) – In HIV‑positive patients, effective ART can restore immunity and lead to regression of KS lesions in up to 80% of cases (CDC).
• Chemotherapy – Liposomal daunorubicin or doxorubicin is first‑line for rapidly progressive KS; paclitaxel is an alternative.
• Immunotherapy – Interferon‑α has activity but is limited by side effects. Newer checkpoint inhibitors (e.g., pembrolizumab) are being studied in clinical trials.
• Targeted agents – Oral mTOR inhibitors (sirolimus) are useful, especially in transplant‑associated KS where they can simultaneously reduce immunosuppression.
• Adjustment of immunosuppression – Reducing or switching calcineurin inhibitors to mTOR inhibitors often leads to lesion regression in transplant patients.

Supportive and Home Care Measures

• Good skin hygiene; avoid trauma that could cause bleeding.
• Use mild soap and non‑irritating moisturizers.
• Protect lesions from sun exposure with broad‑spectrum sunscreen (SPF 30+).
• Maintain a balanced diet and stay hydrated to support overall immune health.
• Quit smoking and limit alcohol, as these can impair wound healing.

Prevention Tips

Because HHV‑8 infection is a prerequisite for KS, prevention focuses on reducing viral transmission and preserving immune function.

• Practice safe sex – Use condoms, limit number of partners, and consider regular HHV‑8 screening in high‑risk populations.
• Avoid sharing needles or personal items that may be contaminated with blood (e.g., razors, toothbrushes).
• Adhere to antiretroviral therapy if HIV‑positive; sustained viral suppression markedly lowers KS risk.
• Follow transplant medication protocols and attend routine follow‑up visits to keep immunosuppression at the lowest effective level.
• Vaccinations – While there is no vaccine for HHV‑8, staying up‑to‑date on influenza, pneumococcal, and other vaccines helps prevent secondary infections that can further compromise immunity.
• Healthy lifestyle – Regular exercise, adequate sleep, and stress management enhance immune surveillance.

Emergency Warning Signs

Key Take‑aways

Kaposi lesions are a visible sign of an underlying vascular tumor driven by HHV‑8 and immune dysfunction. While some forms are slow‑growing and may be managed conservatively, others—particularly in the context of HIV or organ transplantation—can become aggressive. Early recognition, appropriate biopsy, and tailored therapy (including ART for HIV) are essential for optimal outcomes. Maintaining immune health and practicing safe behaviors are the best strategies for prevention.